FindTrial
Sign In

Developing a novel in vitro Cancer-on-Chip platform to study chemotherapy and radiotherapy sensitivity in head and neck cancer patients

Establishment and validation of a microfluidic 3D Cancer-on-Chip platform to study chemo and radio-sensitivity in advanced head and neck cancer patients. - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062196
Enrollment
50
Registered
2024-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: nil: nil

Sponsors

Sanjiban Chakrabarty
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: locally advanced HNSCC planned for treatment with definitive radiotherapy with or without concurrent chemotherapy. For recurrent patients, locoregional persistence or recurrence following definitive radiotherapy with or without chemotherapy. Metastatic recurrence could also be included, if biopsy is feasible.

Exclusion criteria

Exclusion criteria: 1) Age above 70 years, 2) Medically compromised, 3) Low performance status, 4) unwillingness to participate, 5) Unwilling/unfit for tumor directed treatment for recurrent disease.

Design outcomes

Primary

MeasureTime frame
Development of a microfluidic-based platform to study radiation and drug response in ex vivo patient-derived tumor slice culture.Timepoint: 4 years.—

Secondary

MeasureTime frame
Identification of novel genes and pathways responsible for radio-resistance.Timepoint: 3 years—

Countries

India

Contacts

Public ContactSanjiban Chakrabarty

Manipal School of Life Sciences

sanjiban.c@manipal.edu9986297508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026